ArticleSmall (Weinheim an der Bergstrasse, Germany)2022
Leveraging Nanomechanical Perturbations in Raman Spectro-Immunoassays to Design a Versatile Serum Biomarker Detection Platform.
Article in Small (Weinheim an der Bergstrasse, Germany), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 19 citations in OpenAlex.
- Spectral Super-Resolution Colloidal SERS Spectroscopy for Multiplexed Detection of Protein Biomarkers.Nano letters · 2026Article
- Deep Learning-Powered Colloidal Digital SERS for Precise Monitoring of Cell Culture Media.Nano letters · 2025Article
- Deep Learning-Powered Colloidal Digital SERS for Precise Monitoring of Cell Culture Media.bioRxiv : the preprint server for biology · 2025Article
- Gold Nanoprism Enhanced SERS Aptasensor for Simultaneous Detection of Thrombin and VEGF.Sensors and actuators. B, Chemical · 2025Article
- Plasmonic Gold Prism Array for Digital Surface-Enhanced Raman Spectroscopy Sensing.The journal of physical chemistry. C, Nanomaterials and interfaces · 2024Article
- Label-free plasmonic spectral profiling of serum DNA.Biosensors & bioelectronics · 2024Article
- Quantitative Detection of Thyroid-Stimulating Hormone in Patient Samples with a Nanomechanical Single-Antibody Spectro-Immunoassay.Small (Weinheim an der Bergstrasse, Germany) · 2024Article
- Self-Assembled Bimetallic Au-Ag Nanorod Vertical Array for Single Molecule Plasmonic Sensing.ACS applied nano materials · 2024Article
- Variational Mode Decomposition for Raman Spectral Denoising.Molecules (Basel, Switzerland) · 2023Article
- Luminescent Guests Encapsulated in Metal-Organic Frameworks for Portable Fluorescence Sensor and Visual Detection Applications: A Review.Biosensors · 2023Review
- Pyramidal hyperbolic metasurfaces enhance spontaneous emission of nitrogen-vacancy centers in nanodiamond.Advanced optical materials · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
While immunoassays are pivotal to medical diagnosis and bioanalytical chemistry, the current landscape of public health has catalyzed an important shift in the requirements of immunoassays that demand innovative solutions. For example, rapid, label-free, and low-cost screening of a given analyte is required to inform the best countermeasures to combat infectious diseases in a timely manner. Yet, the current design of immunoassays cannot accommodate such requirements as constraint by accumulative challenges, such as repeated incubation and washing, and the need of two types of antibodies in the sandwich format. To provide a potential solution, herein, a plasmonic Raman immunoassay with single-antibody, multivariate regression, and shift-of-peak strategies, coined as the PRISM assay, for serum biomarkers detection, is reported. The PRISM assay relies on Raman reporter-antibody conjugates to capture analytes on a plasmonic substrate. The ensuing nanomechanical perturbations to vibration of Raman reporters induce subtle but characteristic spectral changes that encode rich information related to the captured analytes. By fusing Raman spectroscopy and chemometric analysis, both Raman frequency shift- and multivariate regression models for sensitive detection of biomarkers are developed. The PRISM assay is expected to find a wide range of applications in clinical diagnosis, food safety surveillance, and environmental monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.